UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus

Clinical infectious diseases, 2021-07, Vol.73 (2), p.e485-e493

2021

Volltextzugriff (PDF)

A green approach for the analysis of emtricitabine bictegravir and tenofovir in a pharmaceutical preparation using novel HPLC and spectrophotometric methods

Biomedical chromatography, 2023-10, Vol.37 (10), p.e5712

2023

Volltextzugriff (PDF)

Therapy initiation and rapid start with Bictegravir/Emtricitabine/Tenofovir Alafenamide in PLWH

Le infezioni in medicina, 2023, Vol.31 (3), p.277-282

Antinori, Andrea

2023

Volltextzugriff (PDF)

Clinical pharmacology of the SingleTablet Regimen (STR) Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)

Le infezioni in medicina, 2023, Vol.31 (3), p.283-289

Di Perri, Giovanni

2023

Volltextzugriff (PDF)

Persistencia de los tratamientos con dolutegravir/lamivudina y bictegravir/emtricitabina/tenofovir-alafenamida en personas con VIH en la práctica real

Farmacia hospitalaria, 2024-07, Vol.48 (4), p.171-175

2024

Volltextzugriff (PDF)

Development of dissolving microneedles for intradermal delivery of the long-acting antiretroviral drug bictegravir

International journal of pharmaceutics, 2023-07, Vol.642, p.123108-123108, Article 123108

2023

Volltextzugriff (PDF)

Simulating HIV Breakthrough and Resistance Development During Variable Adherence to Antiretroviral Treatment

Journal of acquired immune deficiency syndromes (1999), 2021-03, Vol.86 (3), p.369-377

2021

Volltextzugriff (PDF)

2018 FDA drug approvals

Nature reviews. Drug discovery, 2019-02, Vol.18 (2), p.85-89

Mullard, Asher

2019

Volltextzugriff (PDF)

Review of Synthetic Routes and Final Forms of Integrase Inhibitors Dolutegravir, Cabotegravir, and Bictegravir

Organic process research & development, 2019-05, Vol.23 (5), p.716-729

Hughes, David L

2019

Volltextzugriff (PDF)

Biktarvy for the treatment of HIV infection: Progress and prospects

Biochemical pharmacology, 2023-11, Vol.217, p.115862-115862, Article 115862

2023

Volltextzugriff (PDF)

Efectividad, seguridad e impacto económico del régimen de bictegravir/emtricitabina/tenofovir alafenamida en una cohorte de pacientes adultos infectados por VIH-1 en la práctica clínica real

Revista española de quimioterapia, 2021-01, Vol.34 (4), p.315-319

2021

Volltextzugriff (PDF)

Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes

Antimicrobial agents and chemotherapy, 2021-04, Vol.65 (5)

2021

Volltextzugriff (PDF)

Measurement of total and unbound bictegravir concentrations in plasma and cerebrospinal fluid by UHPLC-MS/MS

Journal of pharmaceutical and biomedical analysis, 2020-06, Vol.185, p.113250, Article 113250

2020

Volltextzugriff (PDF)

Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants

Retrovirology, 2018-05, Vol.15 (1), p.37-37, Article 37

2018

Volltextzugriff (PDF)

Inhibition of HTLV-1 Infection by HIV-1 First- and Second-Generation Integrase Strand Transfer Inhibitors

Frontiers in microbiology, 2019-08, Vol.10, p.1877-1877

2019

Volltextzugriff (PDF)

Metabolic effects of switching to Biktarvy (B/F/TAF) in patients with HIV-1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF): The Metabic study

HIV medicine, 2024-05, Vol.25 (9), p.1030-1039

2024

Volltextzugriff (PDF)

Bictegravir alters glucose tolerance in vivo and causes hepatic mitochondrial dysfunction

Antiviral research, 2024-11, Vol.231, p.106020, Article 106020

2024

Volltextzugriff (PDF)

Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era

Journal of acquired immune deficiency syndromes (1999), 2021-03, Vol.86 (3), p.339-343

2021

Volltextzugriff (PDF)

Bictegravir/emtricitabine/tenofovir alafenamide as first-line treatment in naïve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial

International journal of antimicrobial agents, 2024-06, Vol.63 (6), p.107164, Article 107164

2024

Volltextzugriff (PDF)

Development and validation of equilibrium dialysis UHPLC-MS/MS measurement procedures for total and unbound concentrations of bictegravir, dolutegravir, darunavir and doravirine in human plasma. Application to patients with HIV

Clinica chimica acta, 2024-01, Vol.552, p.117678-117678, Article 117678

2024

Volltextzugriff (PDF)

Accumulation of Multiple Mutations In Vivo Confers Cross-Resistance to New and Existing Integrase Inhibitors

The Journal of infectious diseases, 2018-10, Vol.218 (11), p.1773-1776

2018

Volltextzugriff (PDF)

Comparable In Vitro Activities of Second-Generation HIV-1 Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations

Antimicrobial agents and chemotherapy, 2019-12, Vol.64 (1)

2019

Volltextzugriff (PDF)

Eficacia en vida real del cambio a bictegravir/ emtricitabina/tenofovir alafenamida en pacientes previamente tratados con pautas triples que contienen rilpivirina

Revista española de quimioterapia, 2022-01, Vol.35 (4), p.378-381

2022

Volltextzugriff (PDF)

A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis

Antimicrobial agents and chemotherapy, 2021-03, Vol.65 (4)

2021

Volltextzugriff (PDF)

A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain

Clinical infectious diseases, 2019-08, Vol.69 (4), p.657-667

2019

Volltextzugriff (PDF)

1 – 25 von 203

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(159)
Mit Volltextzugriff
(152)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Bictegravir
(182)
Science & Technology
(146)
Life Sciences & Biomedicine
(140)
Hiv
(119)
Dolutegravir
(76)
Emtricitabine
(71)
Infectious Diseases
(70)
Human Immunodeficiency Virus
(66)
Humans
(66)
Hiv Infections - Drug Therapy
(58)
Pharmacology & Pharmacy
(51)
Antiretroviral Therapy
(46)
Drug Therapy
(44)
Immunology
(42)
Anti-Hiv Agents
(40)
Antiretroviral Drugs
(38)
Tenofovir
(36)
Antiretroviral Agents
(35)
Highly Active Antiretroviral Therapy
(32)
Antiviral Agents
(31)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus

A green approach for the analysis of emtricitabine bictegravir and tenofovir in a pharmaceutical preparation using novel HPLC and spectrophotometric methods

Therapy initiation and rapid start with Bictegravir/Emtricitabine/Tenofovir Alafenamide in PLWH

Clinical pharmacology of the SingleTablet Regimen (STR) Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)

Persistencia de los tratamientos con dolutegravir/lamivudina y bictegravir/emtricitabina/tenofovir-alafenamida en personas con VIH en la práctica real

Development of dissolving microneedles for intradermal delivery of the long-acting antiretroviral drug bictegravir

Simulating HIV Breakthrough and Resistance Development During Variable Adherence to Antiretroviral Treatment

2018 FDA drug approvals

Review of Synthetic Routes and Final Forms of Integrase Inhibitors Dolutegravir, Cabotegravir, and Bictegravir

Biktarvy for the treatment of HIV infection: Progress and prospects

Efectividad, seguridad e impacto económico del régimen de bictegravir/emtricitabina/tenofovir alafenamida en una cohorte de pacientes adultos infectados por VIH-1 en la práctica clínica real

Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes

Measurement of total and unbound bictegravir concentrations in plasma and cerebrospinal fluid by UHPLC-MS/MS

Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants

Inhibition of HTLV-1 Infection by HIV-1 First- and Second-Generation Integrase Strand Transfer Inhibitors

Metabolic effects of switching to Biktarvy (B/F/TAF) in patients with HIV-1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF): The Metabic study

Bictegravir alters glucose tolerance in vivo and causes hepatic mitochondrial dysfunction

Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era

Bictegravir/emtricitabine/tenofovir alafenamide as first-line treatment in naïve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial

Development and validation of equilibrium dialysis UHPLC-MS/MS measurement procedures for total and unbound concentrations of bictegravir, dolutegravir, darunavir and doravirine in human plasma. Application to patients with HIV

Accumulation of Multiple Mutations In Vivo Confers Cross-Resistance to New and Existing Integrase Inhibitors

Comparable In Vitro Activities of Second-Generation HIV-1 Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations

Eficacia en vida real del cambio a bictegravir/ emtricitabina/tenofovir alafenamida en pacientes previamente tratados con pautas triples que contienen rilpivirina

A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis

A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain

Suchergebnisse filtern